OCREVUS (ocrelizumab) injection, for intravenous use. Initial U.S. Approval: 2017

OCREVUS (ocrelizumab) injection, for intravenous use. Initial U.S. Approval: 2017

INDICATIONS AND USAGE
OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.
DOSAGE FORMS & STRENGTHS
Injection: 300 mg/10 mL (30 mg/mL) in a single-dose vial.
Manufactured By: Genentech
Prescribing Information URL: Click Here

Access to OCREVUS ™ (ocrelizumab) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.
In the US, ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults or for the treatment of primary progressive MS, in adults. It is administered by intravenous infusion.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.